Germany’s Boehringer Ingelheim and China-based Simcere Pharmaceutical Group unveiled a license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody targeting TL1A and IL-23p19 for the treatment of inflammatory bowel disease (IBD).

SIM0709 is designed to simultaneously block two key pathways implicated in IBD pathogenesis, with pre-clinical in vitro and animal data showing synergistic activity beyond the equivalent monotherapy combination. Boehringer Ingelheim obtains global rights excluding the Greater China territory, while Simcere is eligible for up to EUR 1,058 million in upfront, development, regulatory, and sales milestones, plus royalties on net sales outside greater China.

IBD affects an estimated more than three million people worldwide, and despite advances in anti-inflammatory therapies, many patients continue to experience disease progression and complications such as hospitalization and surgery. The collaboration seeks to accelerate SIM0709’s clinical development as a potential first-in-class treatment that could improve outcomes for patients with ulcerative colitis and Crohn’s disease.

This deal marks Simcere’s second major out-licensing transaction in autoimmune disease and further strengthens Boehringer Ingelheim’s immunology pipeline, reflecting ongoing industry interest in multi-target biologics that can overcome efficacy ceilings in complex immune-mediated diseases.

Industry context

TL1A and IL-23p19 are both validated, high-interest targets in IBD drug development. TL1A is a cytokine upregulated in inflamed intestinal tissue and circulation of IBD patients. It binds to death receptor 3 (DR3), promoting T-cell activation, Th1/Th17 polarization, and fibrotic responses. Several companies have monospecific TL1A antibodies under development, led by Roche with afimkibart and Merck & Co., with tulisokibart, both Phase III stage.

Meanwhile, IL-23, via its p19 subunit, is essential for the maintenance and expansion of Th17 cells, which drive chronic intestinal inflammation. Three IL-23p19 antibodies have been approved for market since 2022: risankizumab (AbbVie) for Crohn’s disease and ulcerative colitis; guselkumab (Janssen) for psoriasis (in late-stage IBD trials); and mirikizumab (Eli Lilly) for ulcerative colitis.

Bispecific antibodies targeting both TL1A and IL-23p19 represent a next-generation approach aiming to surpass the efficacy ceiling of current monotherapies by simultaneously inhibiting two non-redundant, disease-driving pathways.

Other firms with TL1A/IL-23p19 BsAbs under development include Caldera Therapeutics with the Phase I stage CLD-423, and Xencor with the preclinical XmAb412.